E-viri
PDF
Recenzirano
Odprti dostop
-
de Bono, Johann; Mateo, Joaquin; Fizazi, Karim; Saad, Fred; Shore, Neal; Sandhu, Shahneen; Chi, Kim N; Sartor, Oliver; Agarwal, Neeraj; Olmos, David; Thiery-Vuillemin, Antoine; Twardowski, Przemyslaw; Mehra, Niven; Goessl, Carsten; Kang, Jinyu; Burgents, Joseph; Wu, Wenting; Kohlmann, Alexander; Adelman, Carrie A; Hussain, Maha
New England journal of medicine/The New England journal of medicine, 05/2020, Letnik: 382, Številka: 22Journal Article
Up to 30% of patients with metastatic castration-resistant prostate cancer have deleterious mutations in genes involved in homologous recombination repair of DNA damage. The use of the PARP inhibitor olaparib in such patients was associated with longer progression-free survival and a longer time to pain progression than control therapy.
